NICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-...
Read moreNew biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreJ&J sues US government, alleging infringement on First Amendment rights and unfair drug pricing unde...
Read moreIn a move towards curbing rising drug prices, the Inflation Reduction Act (IRA) provision will impos...
Read moreWe summarise ISPOR Annual 2023 including plenary sessions on artificial intelligence, real-world evi...
Read moreOur experts provide a detailed summary of Plenary Session 1 at ISPOR Annual 2023 on global affordabi...
Read moreCMS denies coverage of FDA-approved treatments that target amyloid for Alzheimer's disease unless th...
Read moreThe Project Orbis initiative is an international partnership between medicines regulators in the UK,...
Read moreCollectively, companies still owe AIFA €370 million of the €2.8 billion that industry has to rep...
Read more